MX2022006728A - Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. - Google Patents

Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.

Info

Publication number
MX2022006728A
MX2022006728A MX2022006728A MX2022006728A MX2022006728A MX 2022006728 A MX2022006728 A MX 2022006728A MX 2022006728 A MX2022006728 A MX 2022006728A MX 2022006728 A MX2022006728 A MX 2022006728A MX 2022006728 A MX2022006728 A MX 2022006728A
Authority
MX
Mexico
Prior art keywords
combinations
methods
cancer
treatment
immune checkpoint
Prior art date
Application number
MX2022006728A
Other languages
English (en)
Spanish (es)
Inventor
Shao- Chun Chang
John Kurland
Alejandra Negro
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2022006728A publication Critical patent/MX2022006728A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2022006728A 2020-05-12 2021-05-12 Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. MX2022006728A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Publications (1)

Publication Number Publication Date
MX2022006728A true MX2022006728A (es) 2022-06-09

Family

ID=75977756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006728A MX2022006728A (es) 2020-05-12 2021-05-12 Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.

Country Status (12)

Country Link
US (3) US20210355224A1 (https=)
EP (1) EP4021940A1 (https=)
JP (2) JP7387912B2 (https=)
KR (1) KR20230009354A (https=)
CN (1) CN114729054A (https=)
AU (3) AU2021269832B2 (https=)
BR (1) BR112022021893A2 (https=)
CA (1) CA3158607A1 (https=)
IL (2) IL311936A (https=)
MX (1) MX2022006728A (https=)
TW (2) TWI870592B (https=)
WO (1) WO2021228978A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260077026A1 (en) * 2022-09-07 2026-03-19 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트
WO2025256641A1 (zh) * 2024-06-13 2025-12-18 江苏恒瑞医药股份有限公司 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CA2484052C (en) 2002-04-11 2011-06-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US7135180B2 (en) 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
EP3277318A1 (en) * 2015-04-01 2018-02-07 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
KR102664891B1 (ko) * 2016-06-20 2024-05-13 에프-스타 테라퓨틱스 리미티드 Pd-l1 및 lag-3에 결합하는 결합 분자
MX2019003569A (es) * 2016-09-27 2020-07-22 Oncologie Inc Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
JP2020515637A (ja) * 2017-04-03 2020-05-28 オンコロジー、インコーポレイテッド 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
RU2019138742A (ru) * 2017-05-26 2021-06-28 Бруин Байосаенсис, Инк. Средства для химиоэмболизации
JP2020522486A (ja) * 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
WO2019241742A1 (en) * 2018-06-14 2019-12-19 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
AU2019285344A1 (en) * 2018-06-15 2020-12-10 Mina Therapeutics Limited Combination therapies comprising C/EBP alpha saRNA

Also Published As

Publication number Publication date
EP4021940A1 (en) 2022-07-06
TW202535468A (zh) 2025-09-16
AU2021269832A1 (en) 2022-05-19
WO2021228978A1 (en) 2021-11-18
JP7387912B2 (ja) 2023-11-28
US20240239893A1 (en) 2024-07-18
CN114729054A (zh) 2022-07-08
JP2023524359A (ja) 2023-06-12
AU2024202963B2 (en) 2025-11-20
KR20230009354A (ko) 2023-01-17
AU2024202963A1 (en) 2024-05-30
CA3158607A1 (en) 2021-11-18
IL297640A (en) 2022-12-01
TWI870592B (zh) 2025-01-21
US20210355224A1 (en) 2021-11-18
TW202207976A (zh) 2022-03-01
AU2021269832B2 (en) 2024-09-19
IL311936A (en) 2024-06-01
AU2024266949A1 (en) 2024-12-19
BR112022021893A2 (pt) 2022-12-20
US20220363762A1 (en) 2022-11-17
JP2024016209A (ja) 2024-02-06

Similar Documents

Publication Publication Date Title
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2025008444A (es) Uso de un anticuerpo anti-pd-1 y un anticuerpo anti-cd3 x muc16 biespecifico para el tratamiento de un tumor que expresa muc16
MY191423A (en) Binding molecules specific for cd73 and uses thereof
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
AU2018290532A1 (en) Immunotherapy for hepatocellular carcinoma
ZA201806397B (en) Humanized anti clever-1 antibodies and their use
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
MY208743A (en) Anti-ms4a4a antibodies and methods of use thereof
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
MX2022006147A (es) Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.
MX2022006148A (es) Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit.
ZA202108422B (en) Anti-cd25 for tumour specific cell depletion
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.
AU2019379261A8 (en) Pharmaceutical combination of anti-CEACAM6 and either anti-PD-1 or anti-PD-l1 antibodies for the treatment of cancer
CR20230150A (es) Combinaciones de lurbinectedina